Lataa...
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously performed a...
Tallennettuna:
| Julkaisussa: | Blood Adv |
|---|---|
| Päätekijät: | , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5637393/ https://ncbi.nlm.nih.gov/pubmed/29034364 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016004176 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|